Market Overview:
The global tuberculosis therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of tuberculosis, rising awareness about tuberculosis and its treatment, and the launch of new and innovative drugs. Based on type, the global tuberculosis therapeutics market is segmented into isoniazid, rifampin, pyrazinamide, hydrazine derivatives, miscellaneous anti-tubercular drugs (including prothionamide), ethambutol hydrochloride tablets/capsules (HCl), and other anti-tubercular drugs. Isoniazid accounted for the largest share of this market in 2017 owing to its high efficacy against Mycobacterium tuberculosis strains. Based on application, hospitals accounted for the largest share of this market in 2017 owing to increased patient awareness about available treatments for TB and growing number of patients diagnosed with TB every year.
Product Definition:
Tuberculosis Therapeutics is a term used to describe the use of drugs and other treatments to cure or prevent tuberculosis. Tuberculosis is a serious, often deadly disease caused by infection with the bacterium Mycobacterium tuberculosis. It most commonly affects the lungs, but can also affect other parts of the body. The use of drugs and other treatments to cure or prevent tuberculosis is important because it can help protect people from getting sick and dying from this serious disease.
Isoniazid:
Isoniazid is an anti-tuberculosis drug and is used in the treatment of pulmonary tuberculosis. It works by killing the bacteria that causes TB. Tuberculosis (TB) or Pulmonary Tuberculosis (PTB) is a type of lung infection caused by mycobacterium tuberculosis, one of the strains of bacteria.
Rifampin:
Rifampin is an antibiotic drug used for the treatment of tuberculosis. It works by killing the bacteria that causes tuberculosis. Rifampin can be given with rifamycin or without rifamycin therapy. The drug was approved by the U.S Food and Drug Administration (FDA) in 1995 as a generic, which was later on approved under the name Bactrim among others, in 1997 and 1998 respectively.
Application Insights:
The others application segment held the largest share of the global tuberculosis therapeutics market in 2017. This is due to high usage of these drugs for treating drug-resistant TB. Drug-resistant TB is a major concern as it hinders the effective treatment of multidrug-resistant (MDR) and extensively drug- resistant (XDR) tuberculosis, which results in prolongation of treatment and increased healthcare costs. Thus, increasing use of second line anti-TB drugs for treating MDR or XTB disease is expected to drive demand over the forecast period.
Rifampin was found to be most effective against multidrug resistant TB while ethambutol was observed to be most effective against HIV/AIDS related TB infection. However, there are few side effects associated with their usage such as allergic reactions leading from rifampin therapy that limit its applications in comparison with other anti -tubercular drugs available globally.
Regional Analysis:
Asia Pacific dominated the global market in 2017 and is expected to maintain its position during the forecast period. This can be attributed to increasing prevalence of multi-drug resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB). According to WHO, India has registered 8,068 cases of MDR & XDR pulmonaryTB between January 2016 and November 2017. In addition, growing healthcare infrastructure coupled with rising disposable income is anticipated to fuel growth over the forecast period.
North America held a substantial share in terms of revenue generation owing to high incidence rates of active pulmonary tuberculosis as well as multidrug resistance among strains that remain susceptible toisoniazid are major factors responsible for their dominance. Moreover, government initiatives such as “10x2020†initiative aimed at reducing incidence rates by 2020 have been taken up across countries like U.S.
Growth Factors:
- Increasing incidence of tuberculosis (TB) across the globe
- Growing demand for novel and effective TB therapies
- Rising public and private investments in TB research and development (R&D)
- Proliferation of new drug regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB)
- Technological advancements in TB diagnosis and treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Tuberculosis Therapeutics Market Research Report
By Type
Isoniazid, Rifampin, Pyrazinamide, Hydrazine Derivatives, Miscellaneous Anti-Tubercular Drugs, Ethambutol, Others
By Application
Hospital, Pharmacy, Clinics, Others
By Companies
Aventis Pharmaceuticals, Sanofi -Aventis, Versapharma Incorporated, Sigma Pharmaceutical Pty, Novartis AG, Hoffmann-La Roche, Bayer Health Care
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
187
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global Tuberculosis Therapeutics Market Report Segments:
The global Tuberculosis Therapeutics market is segmented on the basis of:
Types
Isoniazid, Rifampin, Pyrazinamide, Hydrazine Derivatives, Miscellaneous Anti-Tubercular Drugs, Ethambutol, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aventis Pharmaceuticals
- Sanofi -Aventis
- Versapharma Incorporated
- Sigma Pharmaceutical Pty
- Novartis AG
- Hoffmann-La Roche
- Bayer Health Care
Highlights of The Tuberculosis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Isoniazid
- Rifampin
- Pyrazinamide
- Hydrazine Derivatives
- Miscellaneous Anti-Tubercular Drugs
- Ethambutol
- Others
- By Application:
- Hospital
- Pharmacy
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tuberculosis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tuberculosis therapeutics are medications used to treat tuberculosis. These medications can help to stop the growth of the tuberculosis bacteria, and may also help to prevent future infections from occurring.
Some of the major companies in the tuberculosis therapeutics market are Aventis Pharmaceuticals, Sanofi -Aventis, Versapharma Incorporated, Sigma Pharmaceutical Pty, Novartis AG, Hoffmann-La Roche, Bayer Health Care.
The tuberculosis therapeutics market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tuberculosis Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tuberculosis Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tuberculosis Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tuberculosis Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tuberculosis Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Tuberculosis Therapeutics Market Size and Y-o-Y Growth
4.5.2 Tuberculosis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Tuberculosis Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tuberculosis Therapeutics Market Size Forecast by Type
5.2.1 Isoniazid
5.2.2 Rifampin
5.2.3 Pyrazinamide
5.2.4 Hydrazine Derivatives
5.2.5 Miscellaneous Anti-Tubercular Drugs
5.2.6 Ethambutol
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tuberculosis Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tuberculosis Therapeutics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Clinics
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tuberculosis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tuberculosis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tuberculosis Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Tuberculosis Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tuberculosis Therapeutics Market Size Forecast by Type
9.6.1 Isoniazid
9.6.2 Rifampin
9.6.3 Pyrazinamide
9.6.4 Hydrazine Derivatives
9.6.5 Miscellaneous Anti-Tubercular Drugs
9.6.6 Ethambutol
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tuberculosis Therapeutics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.10.3 Clinics
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tuberculosis Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Tuberculosis Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tuberculosis Therapeutics Market Size Forecast by Type
10.6.1 Isoniazid
10.6.2 Rifampin
10.6.3 Pyrazinamide
10.6.4 Hydrazine Derivatives
10.6.5 Miscellaneous Anti-Tubercular Drugs
10.6.6 Ethambutol
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tuberculosis Therapeutics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.10.3 Clinics
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tuberculosis Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tuberculosis Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tuberculosis Therapeutics Market Size Forecast by Type
11.6.1 Isoniazid
11.6.2 Rifampin
11.6.3 Pyrazinamide
11.6.4 Hydrazine Derivatives
11.6.5 Miscellaneous Anti-Tubercular Drugs
11.6.6 Ethambutol
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tuberculosis Therapeutics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.10.3 Clinics
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tuberculosis Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Tuberculosis Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tuberculosis Therapeutics Market Size Forecast by Type
12.6.1 Isoniazid
12.6.2 Rifampin
12.6.3 Pyrazinamide
12.6.4 Hydrazine Derivatives
12.6.5 Miscellaneous Anti-Tubercular Drugs
12.6.6 Ethambutol
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tuberculosis Therapeutics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.10.3 Clinics
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tuberculosis Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tuberculosis Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tuberculosis Therapeutics Market Size Forecast by Type
13.6.1 Isoniazid
13.6.2 Rifampin
13.6.3 Pyrazinamide
13.6.4 Hydrazine Derivatives
13.6.5 Miscellaneous Anti-Tubercular Drugs
13.6.6 Ethambutol
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tuberculosis Therapeutics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.10.3 Clinics
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tuberculosis Therapeutics Market: Competitive Dashboard
14.2 Global Tuberculosis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aventis Pharmaceuticals
14.3.2 Sanofi -Aventis
14.3.3 Versapharma Incorporated
14.3.4 Sigma Pharmaceutical Pty
14.3.5 Novartis AG
14.3.6 Hoffmann-La Roche
14.3.7 Bayer Health Care
